KoreaTimes - Bio

The Korea Times

Entertainment & Arts

SCMP
Asia

The Korea Times

Entertainment & Arts

SCMP
Asia

The Korea Times

Business

Bio

Sat, March 25, 2023 | 04:37

Samsung Biologics highlights essentials for global pharma-CDMO partnerships

Samsung Biologics highlights essentials for global pharma-CDMO partnerships

FRANKFURT - Samsung Biologics, a world-leading contract development and manufacturing organization (CDMO) company that develops and produces drugs for its clients, said demand for biomedicine will exceed supply from 2026, adding that finding the best partner to outsource production is becoming more important for global pharmaceutical companies, according to its executive, Tue...

Baek Byung-yeul | 2022-11-01 19:05

Celltrion seeks new partnerships at CPhI bio exhibition

Celltrion seeks new partnerships at CPhI bio exhibition

FRANKFURT - Celltrion, a Korea-based biopharmaceutical company, is seeking to secure new partnerships at the CPhI bio pharmaceutical exhibition by opening an independent booth, the company said Tuesday. The exhibition is held every year touring major European cities. This year's event is in Frankfurt, Germany, for three days through Thursday, providing opportunities for medic...

Baek Byung-yeul | 2022-11-01 16:35

Samsung Biologics seeks to expand partnerships at CPhI

Samsung Biologics seeks to expand partnerships at CPhI

FRANKFURT - Samsung Biologics and other biotechnology companies in Korea will showcase their technologies and seek more business opportunities with global buyers at this year's CPhI bio pharmaceutical exhibition, according to the companies, Monday. The CPhI is an annual exhibition in the bio pharmaceutical industry held in Europe. This year's event will be held for three days...

Baek Byung-yeul | 2022-10-31 15:36

HLB Science to showcase sepsis treatment at BIO-Europe

HLB Science to showcase sepsis treatment at BIO-Europe

HLB Science, an affiliate of HLB Group, said Friday that it will showcase its sepsis treatment to medical experts and buyers at the BIO-Europe conference, which will be held virtually from Nov. 2 to 4. BIO-Europe is one of the largest pharmaceutical conferences in the biotechnology industry where around 2,000 companies from over 60 countries participate every year to discuss ...

Baek Byung-yeul | 2022-10-28 14:50

SK Bioscience aims to address vaccine inequality through global partnership

SK Bioscience aims to address vaccine inequality through global partnership

SK Bioscience, which developed Korea's first COVID-19 vaccine, SKYCovione, said Thursday that the biotech company aims to address the issue of vaccine inequality by intensifying collaboration with international organizations so that people living in low-income countries will be easily able to prevent life-threatening diseases. Rich, developed countries were the first to get a...

Baek Byung-yeul | 2022-10-20 16:43

HLB completes preparatory meeting with FDA for approval of liver cancer drug

HLB completes preparatory meeting with FDA for approval of liver cancer drug

Local biotech company HLB is stepping up efforts to win a novel drug approval in the United States for its liver cancer treatment Rivoceranib, after completing a pre-new drug application (NDA) meeting with the U.S. Food and Drug Administration (FDA), the company said Wednesday. The company said its U.S. subsidiary Elevar Therapeutics and China's Jiangsu Hengrui Medicine compl...

Baek Byung-yeul | 2022-10-12 17:01

Samsung chief vows to invest $5.2 bil. to create huge lead for bio business

Samsung chief vows to invest $5.2 bil. to create huge lead for bio business

Samsung Electronics Vice Chairman Lee Jae-yong has vowed to invest 7.5 trillion won ($5.2 billion) in the company's biotechnology firm by 2032 to achieve a huge lead with its competitors, Samsung Group said Tuesday. The Samsung chief attended the ceremony for the completion of Samsung Biologics' fourth drug manufacturing plant in Songdo, Incheon. The plant, which went into op...

Baek Byung-yeul | 2022-10-11 16:47

Samsung Biologics launches bispecific antibody platform S-DUAL

Samsung Biologics launches bispecific antibody platform S-DUAL

Samsung Biologics launched S-DUAL, a bispecific antibody platform developed with its own technology with an aim to improve its capability in the contract-based drug development business, the company said Thursday. Bispecific antibodies act on two factors simultaneously, not just one factor, which is more effective than a monospecific antibody that acts on only one factor.

Baek Byung-yeul | 2022-10-06 16:46

Korean biotech firms show off capabilities in Europe

Korean biotech firms show off capabilities in Europe

HLB, Celltrion, NeoImmuneTech and other Korean biotech companies confirmed their competitiveness in Europe as they showcased their new drug development capabilities at the European Society for Medical Oncology (ESMO) Congress, an annual medical oncology fair to share the latest developments in cancer research, they said Tuesday. This year's ESMO Congress was held in Paris for...

Baek Byung-yeul | 2022-09-13 16:46

HLB's liver cancer treatment shows longest overall survival

HLB's liver cancer treatment shows longest overall survival

Local biotech company HLB said its liver cancer treatment candidate Rivoceranib showed over 22 months of overall survival in its Phase 3 clinical trials, the longest in any liver cancer treatment, the company said, Thursday. The company said it plans to hold a meeting with the U.S. Food and Drug Administration (FDA) to apply for approval for new drugs, given the effectiveness...

Baek Byung-yeul | 2022-09-08 14:20

1 2 3 4 5 6 7 8

Top 10 Stories

1	Zoo shares sad story of what caused Sero the zebra to escape

2	Burnout: Cardiothoracic surgery residents work 102 hours a week

3	More companies adopt electronic voting amid increase in shareholder activism

4	North Korea will pay price for reckless provocations, warns Yoon

5	Second daughter of Daesang chairman promoted to vice president

6	Churches, Seoul gov't unite to fight low birthrate

7	What's next for Do Kwon?

8	FTC criticized for delaying approval for Hanwha's acquisition of DSME

9	Genesis launches 2023 G90 sedan

10	Over 70% of firms unwilling to embrace longer workweek

DARKROOM